Literature DB >> 20006402

EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.

Benoit Terris1, Catherine Cavard, Christine Perret.   

Abstract

BACKGROUND & AIMS: Cancer progression/metastases and embryonic development share many properties including cellular plasticity, dynamic cell motility, and integral interaction with the microenvironment. We hypothesized that the heterogeneous nature of hepatocellular carcinoma (HCC), in part, may be owing to the presence of hepatic cancer cells with stem/progenitor features.
METHODS: Gene expression profiling and immunohistochemistry analyses were used to analyze 235 tumor specimens derived from 2 recently identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC). These subtypes differed in their expression of AFP, a molecule produced in the developing embryo, and EpCAM, a cell surface hepatic stem cell marker. Fluorescence-activated cell sorting was used to isolate EpCAM(+) HCC cells, which were tested for hepatic stem/progenitor cell properties.
RESULTS: Gene expression and pathway analyses revealed that the EpCAM(+) AFP(+) HCC subtype had features of hepatic stem/progenitor cells. Indeed, the fluorescence-activated cell sorting-isolated EpCAM(+) HCC cells displayed hepatic cancer stem cell-like traits including the abilities to self-renew and differentiate. Moreover, these cells were capable of initiating highly invasive HCC in nonobese diabetic, severe combined immunodeficient mice. Activation of Wnt/beta-catenin signaling enriched the EpCAM(+) cell population, whereas RNA interference-based blockage of EpCAM, a Wnt/beta-catenin signaling target, attenuated the activities of these cells.
CONCLUSIONS: Taken together, our results suggest that HCC growth and invasiveness is dictated by a subset of EpCAM(+) cells, opening a new avenue for HCC cancer cell eradication by targeting Wnt/beta-catenin signaling components such as EpCAM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006402     DOI: 10.1016/j.jhep.2009.10.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  83 in total

Review 1.  Therapeutic application of stem cells in gastroenterology: an up-date.

Authors:  Patrizia Burra; Debora Bizzaro; Rachele Ciccocioppo; Fabio Marra; Anna Chiara Piscaglia; Laura Porretti; Antonio Gasbarrini; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

2.  Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.

Authors:  Leo L Studach; Stephan Menne; Stefano Cairo; Marie Annick Buendia; Ronald L Hullinger; Lydie Lefrançois; Philippe Merle; Ourania M Andrisani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 3.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study.

Authors:  Scott M Thompson; Matthew R Callstrom; Kim A Butters; Shari L Sutor; Bruce Knudsen; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-23       Impact factor: 2.740

6.  Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform.

Authors:  Priya Gopinathan; Lien-Yu Hung; Chih-Hung Wang; Nai-Jung Chiang; Yu-Chun Wang; Yan-Shen Shan; Gwo-Bin Lee
Journal:  Biomicrofluidics       Date:  2017-07-05       Impact factor: 2.800

7.  Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.

Authors:  Da-Eun Nam; Angelina Angelucci; Dahsom Choi; Arnold Leigh; Hae Chang Seong; Young S Hahn
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

8.  Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway.

Authors:  Zhi Zhang; Huiqing Wen; Jun Weng; Lei Feng; Hongya Liu; Xiaojun Hu; Fanhong Zeng
Journal:  Cell Cycle       Date:  2019-08-05       Impact factor: 4.534

9.  Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.

Authors:  Ranju Ralhan; Helen C-H He; Anthony K-C So; Satyendra C Tripathi; Manish Kumar; Md Raghibul Hasan; Jatinder Kaur; Lawrence Kashat; Christina MacMillan; Shyam Singh Chauhan; Jeremy L Freeman; Paul G Walfish
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.

Authors:  Ranju Ralhan; Jun Cao; Terence Lim; Christina Macmillan; Jeremy L Freeman; Paul G Walfish
Journal:  BMC Cancer       Date:  2010-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.